The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
The new business model of the biopharmaceutical industry that focuses on the unmet needs of smaller patient populations has diversified today’s pipelines and brought new hope to patient care.
In its own pursuit to improve the quality of life for patients in need, Kaleido Biosciences, a clinical-stage healthcare company, has focused its efforts on Microbiome Metabolic Therapies (MMT™) to help address a variety of diseases and conditions. Their lead candidate, KB195, is intended to treat urea cycle disorder (UCD), which affects a small population of patients who inherit this serious, rare and life-threatening disease. To bring KB195 to patients, Kaleido needed an IND filed by the end of its first year. And as a small company, it lacked the resources to accomplish this on its own, so it had to consider an alternative yet efficient route to meet its aggressive timeline.